RSV疫苗再遭“打击”。 日前，FDA 发布公告，要求辉瑞和GSK对其已被批准上的RSV疫苗的标签进行修改，添加有关吉兰-巴雷综合征风险的新警告。 CSO企业在制药的路上越走越远。 1月8日，康哲药业宣布，通过全资附属公司与Alpha ...

Kotak Strategic Situations India Fund II, which is managed by Kotak Alternate Asset Managers Ltd, said Friday that it ...

截至2025年1月，卡替拉韦长效方案是国内首个且唯一获国家药监局批准上市的用于HIV暴露前预防的长效注射针剂。作为一种HIV-1整合酶链转移抑制剂 (INSTI)，卡替拉韦长效方案仅需每年注射最少6次即可实现HIV暴露前预防。使用者将在前两个月内接受每月600mg (3ml)的起始注射，随后每两个月接受一次600mg (3ml)的继续注射。

葛兰素史克（以下简称“GSK”）今日宣布其HIV暴露前预防长效药物艾普特®（卡替拉韦注射液）正式上市，用于有感染风险的成人和青少年（体重≥35kg）进行HIV-1暴露前预防（PrEP），以降低性传播感染HIV-1的风险，结合安全的性行为措施以达到更好 ...

Kotak Strategic Situations India Fund II has invested Rs 940 Crore in Neuberg Diagnostics to support its inorganic expansion ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of ...

聚焦健康中国 药品 （第一健康报道北京 品宣部）TCE（ T Cell Engager，T细胞接合器）双抗交易持续火爆，跨国药企还在疯狂“下单”。近日，一家聚焦自身免疫领域的美国药企Candid Therape ...

The 30th edition of the Dubai International Pharmaceuticals and Technologies Conference and Exhibition – DUPHAT 2025 ...

据外媒新闻，美国FDA要求辉瑞和葛兰素史克（GSK）生产的呼吸道合胞病毒（RSV）疫苗须在标签上增加有关罹患吉兰-巴雷综合征（GBS）风险的警告。吉兰-巴雷综合征是一种罕见的神经系统疾病，其病因可能与感染和免疫反应有关，特征性症状为对称性的肢体无力、 ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

In a footnote of his opinion, Judge Joshua Roberts wrote, “A more cynical view of the circumstances is that plaintiffs’ ...